reports
- Research Team ACF
BrainStorm Cell Therapeutics (BCLI) - Fundamentals Update 09042025
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). Recent micro capitalization and patent development buy time for non-dilutive funding to be secured. BCLI’s Nasdaq compliance for minimum price was regained in late Oct 24, which helps maintain capital access. Market still significantly below ACF’s base-case NPV ($650M–$700M). While new bridging funding was announced, no new major funding or rerating events...
- Research Team ACF
BrainStorm Cell Therapeutics (BCLI) Update 11112024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). BLCI’s Expanded Access Program (EAP), a compassionate use study, delivered >96% probability that BCLI’s NurOwn® treatment was responsible for an improved survival rate in a test group of 10 ALS patients. BCLI recently regained Nasdaq price compliance, released two posters for NurOwn® and presented at Maxim’s healthcare summit. We infer that BCLI has a reas...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.